Carisma anticipates that its cash and cash equivalents of $56.5 million as of March 31, 2024, combined with the expected cost savings from implementing the revised operating plan, are sufficient to sustain its planned operations into the third quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics appoints Eugene Kennedy as Chief Medical Officer
- Carisma Therapeutics initiated with a Buy at BTIG
- Carisma Therapeutics price target lowered to $9 from $11 at H.C. Wainwright
- Carisma Therapeutics’ Compliance Hurdle: Navigating Anti-Kickback and Fraud Laws in the Pharmaceutical Landscape
- Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results